Description: Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Home Page: www.ocugen.com
11 Great Valley Parkway
Malvern,
PA
19355
United States
Phone:
484 328 4701
Officers
| Name | Title |
|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman |
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development |
| Mr. Ramesh Ramachandran C.M.A., CPA, M.B.A. | Principal Financial Officer & Principal Accounting Officer |
| John Kouch J.D. | General Counsel |
| Ms. Tiffany J. Hamilton M.B.A. | AVP & Head of Corporate Communications |
| Ms. Kristen Craft | Head of People & Culture |
| Mr. Michael Shine M.B.A. | Senior Vice President of Commercial |
| Ms. Jyothy Pillai M.S. | VP & Head of Regulatory & Quality |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 15.1057 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.3261 |
| Price-to-Sales TTM: | 51.6628 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 65 |